S&P 500   4,566.48
DOW   35,741.15
QQQ   377.93
S&P 500   4,566.48
DOW   35,741.15
QQQ   377.93
S&P 500   4,566.48
DOW   35,741.15
QQQ   377.93
S&P 500   4,566.48
DOW   35,741.15
QQQ   377.93

United Therapeutics Stock Forecast, Price & News

+0.33 (+0.17 %)
(As of 10/25/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume503,475 shs
Average Volume353,376 shs
Market Capitalization$8.60 billion
P/E Ratio18.59
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

United Therapeutics logo

About United Therapeutics

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It also involves in the research and development of new indications and delivery devices for its product and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.48 billion
Cash Flow
$11.56 per share
Book Value
$76.40 per share


Net Income
$514.80 million




Market Cap
$8.60 billion
Next Earnings Date
10/27/2021 (Estimated)

Social Links


Overall MarketRank

2.47 out of 5 stars

Medical Sector

139th out of 1,360 stocks

Pharmaceutical Preparations Industry

58th out of 667 stocks

Analyst Opinion: 2.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 2.5 5 -4 -3 -2 -1 -

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

Is United Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" United Therapeutics stock.
View analyst ratings for United Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than United Therapeutics?

Wall Street analysts have given United Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but United Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting United Therapeutics?

United Therapeutics saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 2,470,000 shares, a drop of 23.8% from the August 31st total of 3,240,000 shares. Based on an average daily trading volume, of 324,500 shares, the days-to-cover ratio is presently 7.6 days. Currently, 5.6% of the company's stock are short sold.
View United Therapeutics' Short Interest

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for United Therapeutics

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) issued its quarterly earnings results on Wednesday, August, 4th. The biotechnology company reported $3.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.02 by $0.63. The biotechnology company earned $446.50 million during the quarter, compared to analyst estimates of $378.54 million. United Therapeutics had a net margin of 29.60% and a trailing twelve-month return on equity of 13.69%. United Therapeutics's revenue was up 23.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.68 earnings per share.
View United Therapeutics' earnings history

How has United Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

United Therapeutics' stock was trading at $93.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, UTHR shares have increased by 103.6% and is now trading at $191.34.
View which stocks have been most impacted by COVID-19

What price target have analysts set for UTHR?

8 Wall Street analysts have issued 1 year price targets for United Therapeutics' shares. Their forecasts range from $196.00 to $275.00. On average, they anticipate United Therapeutics' share price to reach $224.38 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price.
View analysts' price targets for United Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the following people:
  • Martine A. Rothblatt, Chairman & Chief Executive Officer
  • Michael Ian Benkowitz, President & Chief Operating Officer
  • James Christopher Edgemond, Chief Financial Officer & Treasurer
  • Paul A. Mahon, Secretary, Executive VP & General Counsel
  • Dewey Steadman, Head-Investor Relations

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics CEO Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among United Therapeutics' employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), (CELG), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Robeco Institutional Asset Management B.V. (0.81%), Wedge Capital Management L L P NC (0.35%), Virginia Retirement Systems ET AL (0.27%), Frontier Capital Management Co. LLC (0.19%), New York State Teachers Retirement System (0.13%) and Assenagon Asset Management S.A. (0.10%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends for United Therapeutics

Which institutional investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Wedge Capital Management L L P NC, Frontier Capital Management Co. LLC, Robeco Institutional Asset Management B.V., Virginia Retirement Systems ET AL, Greylin Investment Mangement Inc., Nisa Investment Advisors LLC, and State of Alaska Department of Revenue. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Christopher Patusky, Judy D Olian, Paul A Mahon, and Raymond Dwek.
View insider buying and selling activity for United Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying United Therapeutics stock?

UTHR stock was purchased by a variety of institutional investors in the last quarter, including Beck Bode LLC, Polianta Ltd, New England Research & Management Inc., Fifth Third Bancorp, Crossmark Global Holdings Inc., Joel Isaacson & Co. LLC, DekaBank Deutsche Girozentrale, and New York State Teachers Retirement System.
View insider buying and selling activity for United Therapeutics
or or view top insider-buying stocks.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $191.34.

How much money does United Therapeutics make?

United Therapeutics has a market capitalization of $8.60 billion and generates $1.48 billion in revenue each year. The biotechnology company earns $514.80 million in net income (profit) each year or $11.54 on an earnings per share basis.

How many employees does United Therapeutics have?

United Therapeutics employs 950 workers across the globe.

When was United Therapeutics founded?

United Therapeutics was founded in 1996.

What is United Therapeutics' official website?

The official website for United Therapeutics is www.unither.com.

Where are United Therapeutics' headquarters?

United Therapeutics is headquartered at 1040 SPRING ST, SILVER SPRING MD, 20910.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at (301) 608-9292 or via email at [email protected].

This page was last updated on 10/26/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.